People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arialys Therapeutics, Inc. | — | Biotechnology | Series A | $29.1M | $49.2M | 2022 |
Brian Slingsby, M.D., Ph.D., M.P.H. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Slingsby, M.D., Ph.D., M.P.H. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Hurwitz | 1 | 9 |
| Tighe Reardon | 1 | 7 |
| Jay Lichter, Ph.D. | 1 | 5 |
| Peter Flynn, Ph.D. | 1 | 1 |
| Ashish Xavier, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.